Business Description
GRI Bio Inc
NAICS : 541714
SIC : 2834
ISIN : US3622AW1069
Description
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 26.91 | |||||
Equity-to-Asset | 0.61 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History |
---|
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 18.46 | |||||
9-Day RSI | 21.09 | |||||
14-Day RSI | 22.53 | |||||
6-1 Month Momentum % | -87.49 | |||||
12-1 Month Momentum % | -99.07 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.64 | |||||
Quick Ratio | 2.64 | |||||
Cash Ratio | 2.44 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | -561.58 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -682.88 | |||||
ROA % | -324.44 | |||||
ROIC % | -9257.53 | |||||
ROC (Joel Greenblatt) % | -17522.39 | |||||
ROCE % | -620.38 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.14 | |||||
Price-to-Tangible-Book | 0.14 | |||||
EV-to-EBIT | 0.26 | |||||
EV-to-EBITDA | 0.26 | |||||
EV-to-FCF | 0.34 | |||||
Price-to-Net-Current-Asset-Value | 0.15 | |||||
Price-to-Net-Cash | 0.17 | |||||
Earnings Yield (Greenblatt) % | 384.62 | |||||
FCF Yield % | -1043.33 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GRI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
GRI Bio Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -327.604 | ||
Beta | 0 | ||
Volatility % | 83.26 | ||
14-Day RSI | 22.53 | ||
14-Day ATR ($) | 0.502599 | ||
20-Day SMA ($) | 2.746365 | ||
12-1 Month Momentum % | -99.07 | ||
52-Week Range ($) | 1.6 - 441.704899 | ||
Shares Outstanding (Mil) | 0.6 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
GRI Bio Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
GRI Bio Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
GRI Bio Inc Frequently Asked Questions
What is GRI Bio Inc(GRI)'s stock price today?
The current price of GRI is $1.60. The 52 week high of GRI is $441.70 and 52 week low is $1.60.
When is next earnings date of GRI Bio Inc(GRI)?
The next earnings date of GRI Bio Inc(GRI) is .
Does GRI Bio Inc(GRI) pay dividends? If so, how much?
GRI Bio Inc(GRI) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |